Scholarlink

<p>The rising global prevalence of obesity and associated comorbidities—most notably significantly increased cardiovascular mortality—have long transformed obesity from a&#xa0;cosmetic concern into a&#xa0;disease with substantial morbidity and mortality. Consequently, obesity also places a&#xa0;considerable burden on healthcare systems. Long-term multimodal treatment strategies are necessary to achieve not only weight reduction but also improvements in overall health and quality of life for affected individuals. The current article summarizes currently approved pharmacological treatment options for obesity in Austria, focusing on their efficacy, benefits, and risks. The overview is based on recent clinical trials, regulatory approvals, and national guideline recommendations. Pharmacological therapies, particularly those based on incretin mechanisms, significantly expand the spectrum of obesity management and allow substantial improvements in weight, comorbidities, and cardiometabolic risk factors while maintaining a&#xa0;generally favorable safety profile. Future developments, such as oral glucagon-like peptide‑1 receptor agonists (GLP1-RA) and multi-agonists—some of which are already under investigation in phase&#xa0;III clinical trials—promise additional effective approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medikamentöse Therapie der Adipositas

  • 期刊论文

  • 发表日期：

    2026年2月26日

查看全文
  • Andrea Malzner

摘要

The rising global prevalence of obesity and associated comorbidities—most notably significantly increased cardiovascular mortality—have long transformed obesity from a cosmetic concern into a disease with substantial morbidity and mortality. Consequently, obesity also places a considerable burden on healthcare systems. Long-term multimodal treatment strategies are necessary to achieve not only weight reduction but also improvements in overall health and quality of life for affected individuals. The current article summarizes currently approved pharmacological treatment options for obesity in Austria, focusing on their efficacy, benefits, and risks. The overview is based on recent clinical trials, regulatory approvals, and national guideline recommendations. Pharmacological therapies, particularly those based on incretin mechanisms, significantly expand the spectrum of obesity management and allow substantial improvements in weight, comorbidities, and cardiometabolic risk factors while maintaining a generally favorable safety profile. Future developments, such as oral glucagon-like peptide‑1 receptor agonists (GLP1-RA) and multi-agonists—some of which are already under investigation in phase III clinical trials—promise additional effective approaches.